Review on the Role of Host Immune Response in Protection and Immunopathogenesis during Cutaneous Leishmaniasis Infection (original) (raw)

Abstract

Cutaneous leishmaniasis (CL) is a major public health problem worldwide and spreads to human via the bite of sand flies during blood meal. Following its inoculation, the promastigotes are immediately taken up by phagocytic cells and these leishmania-infected host cells produce proinflammatory cytokines that activate other immune cells and these infected host cells produce more cytokines and reactive nitrogen and oxygen species for efficient control of leishmania infection. Many experimental studies showed that resistance to infection with leishmania paraites is associated with the production of proinflammatory cytokines and activation of CD4+ Th1 response. On the other hand, vulnerability to this parasitic infection is correlated to production of T helper 2 cytokines that facilitate persistence of parasites and disease progression. In addition, some studies have also indicated that CD8+ T cells play a vital role in immune defense through cytokine production and their cytotoxic activ...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (113)

  1. J. Kaur, T. Kaur, and S. Kaur, "Studies on the protective efficacy and immunogenicity of Hsp 70 and Hsp 83 based vaccine formulations in Leishmania donovani infected BALB/c mice," Acta Tropica, vol. 119, no. 1, pp. 50-56, 2011.
  2. J. M. Mutiso, J. C. Macharia, and M. M. Gicheru, "Immuniza- tion with Leishmania vaccine-alum-BCG and montanide ISA 720 adjuvants induces low-grade type 2 cytokines and high levels of IgG2 subclass antibodies in the vervet monkey (Chlorocebus aethiops) model," Scandinavian Journal of Immunology, vol. 76, no. 5, pp. 471-477, 2012.
  3. WHO, Weekly Epidemiological Record, Who, 2016.
  4. P. Desjeux, "Leishmaniasis: current situation and new perspectives," Comparative Immunology, Microbiology and Infectious Diseases, vol. 27, no. 5, pp. 305-318, 2004.
  5. E. Gadisa, A. Genetu, T. Kuru et al., "Leishmania (Kinetoplas- tida): Species typing with isoenzyme and PCR -RFLP from cutaneous leishmaniasis patients in Ethiopia," Experimental Parasitology, vol. 115, no. 4, pp. 339-343, 2007.
  6. E. Negera, E. Gadisa, L. Yamuah et al., "Outbreak of cutaneous leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 102, no. 9, pp. 883-890, 2008.
  7. F. Chappuis, S. Sundar, A. Hailu et al., "Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?," Nature Reviews Microbiology, vol. 5, no. 11, pp. 873-882, 2007.
  8. J. D. Berman, "Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years," Clinical Infectious Diseases, vol. 24, no. 4, pp. 684-703, 1997.
  9. N. M. Abdalla, "Comparative study of immune-diagnostic tools with polymerase chain reaction in sub-clinical leish- maniasis isolates," Journal of Medicine, vol. 12, no. 1, pp. 34-39, 2011.
  10. F. Pratlong, J. Dereure, C. Ravel et al., "Geographical distribu- tion and epidemiological features of Old World cutaneous leishmaniasis foci, based on the isoenzyme analysis of 1048 strains," Tropical Medicine & International Health, vol. 14, no. 9, pp. 1071-1085, 2009.
  11. M. Ameen, "Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics," Clinical and Experimental Dermatology, vol. 35, no. 7, pp. 699-705, 2010.
  12. H. W. Murray, J. D. Berman, C. R. Davies, and N. G. Saravia, "Advances in leishmaniasis," The Lancet, vol. 366, no. 9496, pp. 1561-1577, 2005.
  13. U. Sharma and S. Singh, "Immunology of leishmaniasis," Indian Journal of Experimental Biology, vol. 47, pp. 412-423, 2009.
  14. T. Scharton-Kersten, L. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott, "IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis," The Journal of Immunology, vol. 154, no. 10, pp. 5320-5330, 1995.
  15. L. Soong, C. A. Henard, and P. C. Melby, "Immunopathogen- esis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis," Seminars in Immunopa- thology, vol. 34, no. 6, pp. 735-751, 2012.
  16. P. Kaye and P. Scott, "Leishmaniasis: complexity at the host- pathogen interface," Nature Reviews Microbiology, vol. 9, no. 8, pp. 604-615, 2011.
  17. P. Scott and F. O. Novais, "Cutaneous leishmaniasis: immune responses in protection and pathogenesis," Nature Reviews Immunology, vol. 16, no. 9, pp. 581-592, 2016.
  18. M. S. Bailey and D. N. J. Lockwood, "Cutaneous leishmania- sis," Clinics in Dermatology, vol. 25, no. 2, pp. 203-211, 2007.
  19. T. Kawai and S. Akira, "Toll-like receptors and their crosstalk with other innate receptors in infection and immunity," Immunity, vol. 34, no. 5, pp. 637-650, 2011.
  20. L. Soong, C. A. Henard, and P. C. Melby, "Immunopathogen- esis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis," in Seminars in immuno- pathology, vol. 34, pp. 735-751, Springer, 2012.
  21. J. M. Mutiso, J. C. Macharia, M. M. Gicheru et al., "Immunol- ogy of leishmaniasis," Scientia Parasitologica, vol. 14, no. 2, pp. 51-61, 2013.
  22. L. R. V. Antonelli, W. O. Dutra, R. P. Almeida, O. Bacellar, and K. J. Gollob, "Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mecha- nisms for immunoregulation," Clinical & Experimental Immunology, vol. 136, no. 2, pp. 341-348, 2004.
  23. K. Corware, D. Harris, I. Teo et al., "Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid," Bioma- terials, vol. 32, no. 31, pp. 8029-8039, 2011.
  24. C. I. Brodskyn, A. Barral, V. Boaventura, E. Carvalho, and M. Barral-Netto, "Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis," The Journal of Immunology, vol. 159, no. 9, pp. 4467-4473, 1997.
  25. O. Bacellar, H. Lessa, A. Schriefer et al., "Up-regulation of Th1-type responses in mucosal leishmaniasis patients," Infection and Immunity, vol. 70, no. 12, pp. 6734-6740, 2002.
  26. I. Becker, N. Salaiza, M. Aguirre et al., "_Leishmania_ lipo- phosphoglycan (LPG) activates NK cells through toll-like receptor-2," Molecular and Biochemical Parasitology, vol. 130, no. 2, pp. 65-74, 2003.
  27. C. Nacy, M. S. Meltzer, E. J. Leonard, and D. J. Wyler, "Intra- cellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages," The Journal of Immunology, vol. 127, no. 6, pp. 2381-2386, 1981.
  28. D. Matheoud, N. Moradin, A. Bellemare-Pelletier et al., "Leishmania evades host immunity by inhibiting antigen cross-presentation through direct cleavage of the SNARE VAMP8," Cell Host & Microbe, vol. 14, no. 1, pp. 15-25, 2013.
  29. J. Liese, U. Schleicher, and C. Bogdan, "The innate immune response against _Leishmania_ parasites," Immunobiology, vol. 213, no. 3-4, pp. 377-387, 2008.
  30. G. Kavoosi, S. K. Ardestani, A. Kariminia, and Z. Tavakoli, "Production of nitric oxide by murine macrophages induced by lipophosphoglycan of Leishmania major," The Korean Journal of Parasitology, vol. 44, no. 1, pp. 35-41, 2006.
  31. R. Birnbaum and N. Craft, "Innate immunity and Leishmania vaccination strategies," Dermatologic Clinics, vol. 29, no. 1, pp. 89-102, 2011.
  32. T. Lieke, S. Nyln, L. Eidsmo et al., "Leishmania surface pro- tein gp 63 binds directly to human natural killer cells and inhibits proliferation," Clinical & Experimental Immunology, vol. 153, no. 2, pp. 221-230, 2008.
  33. C. A. Biron, K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather, "Natural killer cells in antiviral defense: 9 Journal of Immunology Research function and regulation by innate cytokines," Annual Review of Immunology, vol. 17, no. 1, pp. 189-220, 1999.
  34. L. L. Lanier, "Up on the tightrope: natural killer cell activation and inhibition," Nature Immunology, vol. 9, no. 5, pp. 495-502, 2008.
  35. M. Bajénoff, B. Breart, A. Y. Huang et al., "Natural killer cell behavior in lymph nodes revealed by static and real-time imaging," Journal of Experimental Medicine, vol. 203, no. 3, pp. 619-631, 2006.
  36. Y. Laouar, F. S. Sutterwala, L. Gorelik, and R. A. Flavell, "Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell inter- feron-γ," Nature Immunology, vol. 6, no. 6, pp. 600-607, 2005.
  37. C. K. Prajeeth, S. Haeberlein, H. Sebald, U. Schleicher, and C. Bogdan, "Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity," Infection and Immunity, vol. 79, no. 7, pp. 2699-2708, 2011.
  38. M. I. S. Duarte, F. F. Tuon, C. Pagliari, M. R. Kauffman, and R. A. Brasil, "Human visceral leishmaniasis expresses Th1 pattern in situ liver lesions," Journal of Infection, vol. 57, no. 4, pp. 332-337, 2008.
  39. K. Müller, G. Zandbergen, B. Hansen et al., "Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice," Medical Microbiology and Immunology, vol. 190, no. 1-2, pp. 73-76, 2001.
  40. S. Nylen, K. Maasho, K. Soderstrom, T. Ilg, and H. Akuffo, "Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma," Clinical and Experimental Immunology, vol. 131, no. 3, pp. 457-467, 2003.
  41. M. Laurenti, M. Gidlund, D. M. Ura, I. L. Sinhorini, C. E. Corbett, and H. Goto, "The role of natural killer cells in the early period of infection in murine cutaneous leishmaniasis," Brazilian Journal of Medical and Biological Research, vol. 32, no. 3, pp. 323-325, 1999.
  42. N. C. Peters, J. G. Egen, N. Secundino et al., "In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies," Science, vol. 321, no. 5891, pp. 970-974, 2008.
  43. G. Van Zandbergen, N. Hermann, H. Laufs, W. Solbach, and T. Laskay, "Leishmania promastigotes release a granulocyte chemotactic factor and induce interleukin-8 release but inhibit gamma interferon-inducible protein 10 production by neutrophil granulocytes," Infection and Immunity, vol. 70, no. 8, pp. 4177-4184, 2002.
  44. C. T. Weaver, R. D. Hatton, P. R. Mangan, and L. E. Harring- ton, "IL-17 family cytokines and the expanding diversity of effector T cell lineages," Annual Review of Immunology, vol. 25, pp. 821-852, 2007.
  45. F. L. Ribeiro-Gomes, N. C. Peters, A. Debrabant, and D. L. Sacks, "Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response," PLoS Pathogens, vol. 8, no. 2, article e1002536, 2012.
  46. G. van Zandbergen, M. Klinger, A. Mueller et al., "Cutting edge: neutrophil granulocyte serves as a vector for Leish- mania entry into macrophages," The Journal of Immunology, vol. 173, no. 11, pp. 6521-6525, 2004.
  47. F. Tacchini-Cottier, C. Zweifel, Y. Belkaid et al., "An immu- nomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leish- mania major," The Journal of Immunology, vol. 165, no. 5, pp. 2628-2636, 2000.
  48. R. Ravindran, K. Anam, B. C. Bairagi et al., "Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy," Infec- tious Immunology, vol. 72, no. 2, pp. 863-870, 2004.
  49. H. Ozbılge, N. Aksoy, M. S. Gurel, and S. Yazar, "IgG and IgG subclass antibodies in patients with active cutaneous leish- maniasis," Journal of Medical Microbiology, vol. 55, no. 10, pp. 1329-1331, 2006.
  50. Y. Gutierrez, G. Palma, L. B. Valderrama, C. V. Santrich, G. H. Salinas, and N. G. Saravia, "Correlation between histopathology, immune response, clinical presentation, and evolution in leishmania Braziliensis infection," The American Journal of Tropical Medicine and Hygiene, vol. 45, no. 3, pp. 281-289, 1991.
  51. P. C. Melby and G. M. Anstead, Immune responses to protozoan parasites Clinical Immunology, vol. 29, MO: M Inter Limited, St. Louis, 2nd edition, 2001.
  52. J. R. Ryan, A. M. Smithyman, G.-H. Rajasekariah, L. Hochberg, J. M. Stiteler, and S. K. Martin, "Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis," Journal of Clinical Microbiology, vol. 40, no. 3, pp. 1037-1043, 2002.
  53. M. Nashleanas and P. Scott, "Activated T cells induce macro- phages to produce NO and control Leishmania major in the absence of tumor necrosis factor receptor p 55," Infection and Immunity, vol. 68, no. 3, pp. 1428-1434, 2000.
  54. K. Varkila, R. Chatelain, L. M. Leal, and R. L. Coffman, "Reconstitution of C.B-17 scid mice with BALB/c T cells ini- tiates a T helper type-1 response and renders them capable of healing Leishmania major infection," European Journal of Immunology, vol. 23, no. 1, pp. 262-268, 1993.
  55. P. Scott, "IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis," The Journal of Immunology, vol. 147, no. 9, pp. 3149-3155, 1991.
  56. P. Freitas-Teixeira, D. Silveira-Lemos, R. C. Giunchetti et al., "Distinct pattern of immunophenotypic features of innate and adaptive immunity as a putative signature of clinical and laboratorial status of patients with localized cutaneous leishmaniasis," Scandinavian Journal of Immunology, vol. 76, no. 4, pp. 421-432, 2012.
  57. A. M. Da-Cruz, R. Bittar, M. Mattos et al., "T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy," Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 2, pp. 251-256, 2002.
  58. S. L. Reiner and R. M. Locksley, "The regulation of immunity to Leishmania major," Annual Review of Immunology, vol. 13, no. 1, pp. 151-177, 1995.
  59. Y. Belkaid, C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks, "CD4+ CD25+ regulatory T cells control Leish- mania major persistence and immunity," Nature, vol. 420, no. 6915, pp. 502-507, 2002.
  60. L. R. Castellano, D. C. Filho, L. Argiro et al., "Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-γ production," Human Immunology, vol. 70, no. 6, pp. 383-390, 2009.
  61. 10 Journal of Immunology Research
  62. R. C. Bittar, R. S. Nogueira, R. Vieira-Gonçalves et al., "T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis," Memórias do Instituto Oswaldo Cruz, vol. 102, no. 5, pp. 625-630, 2007.
  63. A. Gomes-Silva, R. D. C. Bittar, R. D. S. Nogueira et al., "Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?," Clinical & Experimental Immunology, vol. 149, no. 3, pp. 440-444, 2007.
  64. A. Baratta-Masini, A. Teixeira-Carvalho, L. C. Malaquias, W. Mayrink, O. A. Martins-Filho, and R. Corrêa-Oliveira, "Mixed cytokine profile during active cutaneous leishmania- sis and in natural resistance," Frontiers in Bioscience, vol. 12, pp. 839-849, 2007.
  65. R. Reithinger, J. C. Dujardin, H. Louzir, C. Pirmez, B. Alexander, and S. Brooker, "Cutaneous leishmaniasis," The Lancet Infectious Diseases, vol. 7, no. 9, pp. 581-596, 2007.
  66. G. Matsuzaki and M. Umemura, "Interleukin-17 as an effector molecule of innate and acquired immunity against infections," Microbiology and Immunology, vol. 51, no. 12, pp. 1139-1147, 2007.
  67. O. Bacellar, D. Faria, M. Nascimento et al., "Interleukin 17 production among patients with American cutaneous leishmaniasis," Journal of Infectious Diseases, vol. 200, no. 1, pp. 75-78, 2009.
  68. C. Gonzalez-Lombana, C. Gimblet, O. Bacellar et al., "IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection," PLoS Pathogens, vol. 9, no. 3, article e1003243, 2013.
  69. S. L. Kostka, S. Dinges, K. Griewank, Y. Iwakura, M. C. Udey, and E. von Stebut, "IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice," The Journal of Immunol- ogy, vol. 182, no. 5, pp. 3039-3046, 2009.
  70. C. da Silva Santos, V. Boaventura, C. R. Cardoso et al., "CD8 + Granzyme B + -Mediated Tissue Injury vs. CD4 + IFNγ + -Medi- ated Parasite Killing in Human Cutaneous Leishmaniasis," Journal of Investigative Dermatology, vol. 133, no. 6, pp. 1533-1540, 2013.
  71. S. Bertholet, A. Debrabant, F. Afrin et al., "Antigen require- ments for efficient priming of CD8+ T cells by Leishmania major-Infected dendritic cells," Infectious Immunology, vol. 73, no. 10, pp. 6620-6628, 2005.
  72. S. Bertholet, R. Goldszmid, A. Morrot et al., "Leishmania antigens are presented to CD8+ T cells by a transporter asso- ciated with antigen processing-independent pathway in vitro and in vivo," The Journal of Immunology, vol. 177, no. 6, pp. 3525-3533, 2006.
  73. H. Jiang and L. Chess, "An integrated view of suppressor T cell subsets in immunoregulation," The Journal of Clinical Investigation, vol. 114, no. 9, pp. 1198-1208, 2004.
  74. D. L. Woodland and R. W. Dutton, "Heterogeneity of CD4+ and CD8+ T cells," Current Opinion in Immunology, vol. 15, no. 3, pp. 336-342, 2003.
  75. M. N. Rostami, H. Keshavarz, R. Edalat et al., "CD8+ T cells as a source of IFN-γ production in human cutaneous leish- maniasis," PLoS Neglected Tropical Diseases, vol. 4, no. 10, article e845, 2010.
  76. J. A. Trapani and M. J. Smyth, "Functional significance of the perforin/granzyme cell death pathway," Nature Reviews Immunology, vol. 2, no. 10, pp. 735-747, 2002.
  77. J. Hernández-Ruiz, N. Salaiza-Suazo, G. Carrada et al., "CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, In Vitro, by TLR2 agonists," PLoS Neglected Tropical Diseases, vol. 4, no. 11, article e871, 2010.
  78. A. M. Da-Cruz, A. L. Bertho, M. P. Oliveira-Neto, and S. G. Coutinho, "Flow cytometric analysis of cellular infiltrate from American tegumentary leishmaniasis lesions," British Journal of Dermatology, vol. 153, no. 3, pp. 537-543, 2005.
  79. A. L. Bertho, M. A. Santiago, A. M. Da-Cruz, and S. G. Coutinho, "Detection of early apoptosis and cell death in T CD4+ and CD8+ cells from lesions of patients with localized cutaneous leishmaniasis," Brazilian Journal of Medical and Biological Research, vol. 33, no. 3, pp. 317-325, 2000.
  80. D. M. Russo, P. Chakrabarti, and A. Y. Higgins, "Leishmania: naive human T cells sensitized with promastigote antigen and IL-12 develop into potent Th1 and CD8+ cytotoxic effectors," Experimental Parasitology, vol. 93, no. 3, pp. 161-170, 1999.
  81. M. Barral-Netto, A. Barral, C. Brodskyn, E. M. Carvalho, and S. G. Reed, "Cytotoxicity in human mucosal and cutaneous leishmaniasis," Parasite Immunology, vol. 17, no. 1, pp. 21- 28, 1995.
  82. J. Zhu and W. E. Paul, "CD4 T cells: fates, functions, and faults," Blood, vol. 112, no. 5, pp. 1557-1569, 2008.
  83. M. Feuerer, J. A. Hill, D. Mathis, and C. Benoist, "Foxp 3+ regulatory T cells: differentiation, specification, subpheno- types," Nature Immunology, vol. 10, no. 7, pp. 689-695, 2009.
  84. D. Xu, W. L. Chan, B. P. Leung et al., "Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells," Journal of Experimental Medicine, vol. 188, no. 8, pp. 1485-1492, 1998.
  85. E. Bourreau, C. Ronet, E. Darcissac et al., "Intralesional regu- latory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanen- sis," Infection and Immunity, vol. 77, no. 4, pp. 1465-1474, 2009.
  86. P. M. Gray, S. L. Reiner, D. F. Smith, P. M. Kaye, and P. Scott, "Antigen-experienced T cells limit the priming of naive T cells during infection with Leishmania major," The Journal of Immunology, vol. 177, no. 2, pp. 925-933, 2006.
  87. S. G. Hoseini, S. H. Javanmard, S. H. Zarkesh et al., "Regula- tory T-cell profile in early and late lesions of cutaneous leishmaniasis due to Leishmania major," Journal of Research in Medical Sciences, vol. 17, no. 6, p. 513, 2012.
  88. I. J. Suffia, S. K. Reckling, C. A. Piccirillo, R. S. Goldszmid, and Y. Belkaid, "Infected site-restricted Foxp 3+ natural reg- ulatory T cells are specific for microbial antigens," Journal of Experimental Medicine, vol. 203, no. 3, pp. 777-788, 2006.
  89. E. Yurchenko, M. Tritt, V. Hay, E. M. Shevach, Y. Belkaid, and C. A. Piccirillo, "CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence," Journal of Experimental Medicine, vol. 203, no. 11, pp. 2451-2460, 2006.
  90. J. Alexander and F. Brombacher, "T helper 1/t helper 2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?," Frontiers in Immunology, vol. 3, p. 80, 2012.
  91. C. M. Tato and J. J. O'shea, "What does it mean to be just 17?," Nature, vol. 441, no. 7090, pp. 166-167, 2006.
  92. A. Selvapandiyan, R. Dey, S. Gannavaram et al., "Immunity to visceral leishmaniasis using genetically defined live- 11 Journal of Immunology Research attenuated parasites," Journal of Tropical Medicine, vol. 2012, Article ID 631460, 12 pages, 2012.
  93. T. E. Andargie and E. D. Ejara, "Pro-and anti-inflammatory cytokines in visceral leishmaniasis," Journal of Cell Science & Therapy, vol. 6, no. 3, p. 1, 2016.
  94. R. O. Pinheiro and B. Rossi-Bergmann, "Interferon-gamma is required for the late but not early control of Leishmania ama- zonensis infection in C57Bl/6 mice," Memorias do Instituto Oswaldo Cruz, vol. 102, no. 1, pp. 79-82, 2007.
  95. G. Trinchieri, "Interleukin-12 and the regulation of innate resis- tance and adaptive immunity," Nature Reviews Immunology, vol. 3, no. 2, pp. 133-146, 2003.
  96. N. Maspi, A. Abdoli, and F. Ghaffarifar, "Pro-and anti- inflammatory cytokines in cutaneous leishmaniasis: a review," Pathogens and Global Health, vol. 110, no. 6, pp. 247-260, 2016.
  97. F. Dotiwala, S. Mulik, R. B. Polidoro et al., "Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites," Nature Medicine, vol. 22, no. 2, pp. 210-216, 2016.
  98. D. R. Faria, K. J. Gollob, Barbosa J Jr et al., "Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis," Infection and Immunity, vol. 73, no. 12, pp. 7853-7859, 2005.
  99. F. Oliveira, A. Bafica, A. B. Rosato et al., "Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis," The American Journal of Tropical Medicine and Hygiene, vol. 85, no. 1, pp. 70-73, 2011.
  100. Y. Iwakura and H. Ishigame, "The IL-23/IL-17 axis in inflammation," The Journal of Clinical Investigation, vol. 116, no. 5, pp. 1218-1222, 2006.
  101. M. A. Souza, M. C. A. B. Castro, A. P. Oliveira et al., "American tegumentary leishmaniasis: cytokines and nitric oxide in active disease and after clinical cure, with or without chemotherapy," Scandinavian Journal of Immunology, vol. 76, no. 2, pp. 175-180, 2012.
  102. F. O. Novais, L. P. Carvalho, J. W. Graff et al., "Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis," PLoS Pathogens, vol. 9, no. 7, article e1003504, 2013.
  103. R. V. H. de Carvalho, D. S. Lima-Junior, M. V. G. da Silva et al., "_Leishmania_ RNA virus exacerbates Leishmaniasis by subverting innate immunity via TLR3-mediated NLRP3 inflammasome inhibition," Nature Communications, vol. 10, no. 1, p. 5273.
  104. M.-A. Hartley, E. Bourreau, M. Rossi et al., "Leishmaniavirus- dependent metastatic leishmaniasis is prevented by blocking IL-17A," PLoS Pathogens, vol. 12, no. 9, pp. e1005852- e1005819, 2016.
  105. M.-A. Hartley, C. Ronet, H. Zangger, S. M. Beverley, and N. Fasel, "Leishmania RNA virus: when the host pays the toll," Frontiers in Cellular and Infection Microbiology, vol. 2, p. 99, 2012.
  106. C. Théry, S. Amigorena, G. Raposo, and A. Clayton, "Isolation and characterization of exosomes from cell culture supernatants and biological fluids," Current Protocols in Cell Biology, vol. 30, no. 1, pp. 3.22.1-3.22.29, 2006.
  107. J. H. Campos, R. P. Soares, K. Ribeiro, A. C. Andrade, W. L. Batista, and A. C. Torrecilhas, "Extracellular vesicles: role in inflammatory responses and potential uses in vaccination in cancer and infectious diseases," Journal of Immunology Research, vol. 2015, Article ID 832057, 14 pages, 2015.
  108. H. Kalra, G. Drummen, and S. Mathivanan, "Focus on extracellular vesicles: introducing the next small big thing," International Journal of Molecular Sciences, vol. 17, no. 2, p. 170, 2016.
  109. J. M. Silverman, J. Clos, E. Horakova et al., "Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells," The Jour- nal of Immunology Research, vol. 185, no. 9, pp. 5011-5022, 2010.
  110. J. M. Silverman, J. Clos, C. Camargo de' Oliveira et al., "An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macro- phages," Journal of Cell Science, vol. 123, pp. 842-852, 2010.
  111. V. D. Atayde, H. Aslan, S. Townsend, K. Hassani, S. Kamhawi, and M. Olivier, "Exosome secretion by the parasitic protozoan leishmania within the sand fly midgut," Cell Reports, vol. 13, no. 5, pp. 957-967, 2015.
  112. A. Trocolitorrecilhas, R. Tonelli, W. Pavanelli et al., "Trypa- nosoma cruzi: parasite shed vesicles increase heart parasitism and generate an intense inflammatory response," Microbes and Infection, vol. 11, no. 1, pp. 29-39, 2009.
  113. G. Coakley, J. L. McCaskill, J. G. Borger et al., "Extracellular vesicles from a helminth parasite suppress macrophage activation and constitute an effective vaccine for protective immunity," Cell Reports, vol. 19, no. 8, pp. 1545-1557, 2017.